← SynDRA
PRALATREXATE
SynDRA canonical compound SYN0023599 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | DHFR |
|---|
| Mechanism of action | Dihydrofolate reductase inhibitor |
|---|
| Indication | peripheral T-cell lymphoma (PTCL) |
|---|
| Disease area | hematologic malignancy |
|---|
All known targets
- DHFR
- SLC19A1
- FOLR1
- PDF
- SLC46A1
Mechanisms of action (all sources)
- dihydrofolate reductase inhibitor
- DHFR INHIBITOR
- PDF INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ATXN2
- KSYK
- MITF
- NSD2
- PARP1
- SYK
- TFE3
- TP53
Drug classes
- Folate Analog Metabolic Inhibitor
ATC classes
Cross-references
Synonyms
- FOLOTYN
- Folotyn
- 10-Propargyl-10-deazaaminopterin
- folotyn
- Pralatrexato
- NSC-754230
- PDX
- Folotyn (TN)
- HSDB 7786
- Pralatrexate(Folotyn)
- CHEBI:71223
- NSC 754230
- A8Q8I19Q20
- 146464-95-1 (racemic)
- NSC754230
- NCGC00242596-01
- Pralatrexate [USAN]
- Pralatrexate [USAN:INN]
- pralatrexato
- pralatrexatum
- Pralatrexat
- Pralatrexte
- UNII-A8Q8I19Q20
- PRALATREXATE [MI]
- PRALATREXATE [INN]
- PRALATREXATE [JAN]
- PRALATREXATE [HSDB]
- PRALATREXATE [VANDF]
- SCHEMBL21633
- PRALATREXATE [MART.]
- PRALATREXATE [WHO-DD]
- GTPL6840
- Pralatrexate (JAN/USAN/INN)
- CHEMBL1201746
- DTXSID3048578
- SCHEMBL15075302
- BCPP000101
Look up PRALATREXATE in the interactive SynDRA portal →